open access

Vol 70, No 3 (2020)
Other materials agreed with the Editors
Published online: 2020-06-04
Get Citation

Proposals for the modification of diagnostics and combination treatment of breast cancer during the COVID-19 pandemic

Aleksandra Łacko12, Adam Maciejczyk12, Piotr Kasprzak1, Dorota Dupla1, Elżbieta Senkus3, Wojciech Wysocki456, Zbigniew I. Nowecki7, Rafał Matkowski12
·
Nowotwory. Journal of Oncology 2020;70(3):77-84.
Affiliations
  1. Lower Silesian Oncology Centre in Wroclaw, Poland
  2. Faculty of Oncology, Wroclaw Medical University, Poland
  3. Faculty and Clinic of Oncology and Radiotherapy, Medical University of Gdansk, Poland
  4. Clinic of General, Oncological and Vascular Surgery, 5th Military Hospital with Polyclinic in Krakow, Poland
  5. Faculty of Surgery, Department of Medicine and Health Sciences, A. Frycz-Modrzewski Krakow University, Poland
  6. Research Editing Board, M. Sklodowska-Curie National Research Institute of Oncology– National Research Institute in Warsaw, Poland
  7. Clinic of Breast Cancer and Reconstruction Surgery, M. Sklodowska-Curie National Research Institute of Oncology – National Research Institute in Warsaw, Poland

open access

Vol 70, No 3 (2020)
COVID-19
Published online: 2020-06-04

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Proposals for the modification of diagnostics and combination treatment of breast cancer during the COVID-19 pandemic

Journal

Nowotwory. Journal of Oncology

Issue

Vol 70, No 3 (2020)

Article type

Other materials agreed with the Editors

Pages

77-84

Published online

2020-06-04

Page views

864

Article views/downloads

696

DOI

10.5603/NJO.a2020.0018

Bibliographic record

Nowotwory. Journal of Oncology 2020;70(3):77-84.

Authors

Aleksandra Łacko
Adam Maciejczyk
Piotr Kasprzak
Dorota Dupla
Elżbieta Senkus
Wojciech Wysocki
Zbigniew I. Nowecki
Rafał Matkowski

References (30)
  1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020; 21(3): 335–337.
  2. Cortiula F, Pettke A, Bartoletti M, et al. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Annals of Oncology. 2020; 31(5): 553–555.
  3. Curigliano G, Cardoso M, Poortmans P, et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. The Breast. 2020; 52: 8–16.
  4. Zalecenia dla pacjentów onkologicznych w związku z sytuacją epidemiologiczną w kraju. NOWOTWORY J Oncol. 2020; 70(2): 37–38.
  5. Zalecenia Polskiego Towarzystwa Onkologicznego i Polskiego Towarzystwa Chirurgii Onkologicznej w sprawie postępowania z pacjentami onkologicznymi. NOWOTWORY J Oncol. 2020; 70(2): 39–40.
  6. Stanowisko Polskiego Towarzystwa Chirurgii Onkologicznej w sprawie postępowania u chorych na nowotwory wymagających leczenia chirurgicznego w okresie zagrożenia epidemiologicznego. NOWOTWORY J Oncol. 2020; 70(2): 41–42.
  7. Wysocki PJ, Kwinta Ł, Potocki P, et al. Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 – stanowisko Polskiego Towarzystwa Onkologii Klinicznej. NOWOTWORY J Oncol. 2020; 70(2): 43–46.
  8. Society of Breast Imaging Statement on Breast Imaging during the COVID-19 Pandemic. Society of Breast Imaging. https://www.sbi-online.org/Portals/0/Position%20Statements/2020/society-of-breast-imaging-statement-on-breast-imaging-during-COVID19-pandemic.pdf.
  9. Dietz J, Moran M, Isakoff S, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Research and Treatment. 2020; 181(3): 487–497.
  10. World Health Organization. COVID-19: Operational guidance for maintaining essential health services during an outbreak. https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak.
  11. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(8): 1194–1220.
  12. Cardoso F, Senkus E, Costa A, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology. 2018; 29(8): 1634–1657.
  13. American College of Surgeons. COVID-19 Guidelines for Triage of Breast Cancer Patients. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer.
  14. National comprehensive cancer network. Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community. https://www.nccn.org/covid-19/.
  15. The Treatment of Patients With Cancer and Containment of COVID-19: Experiences From Italy. Default Digital Object Group. 2020.
  16. ESMO management and treatment adapted recommendations in the COVID-19 era: Breast cancer. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era.
  17. Coles CE, Aristei C, Bliss J, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology. 2020; 32(5): 279–281.
  18. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. European Journal of Cancer. 2015; 51(4): 451–463.
  19. Vrieling C, Werkhoven Ev, Maingon P, et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial. JAMA Oncol. 2017; 3(1): 42–48.
  20. Braunstein L, Gillespie E, Hong L, et al. Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints—Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States. Adv Radiat Oncol. 2020.
  21. Simcock R, Thomas T, Estes C, et al. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020; 22: 55–68.
  22. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011; 100(1): 93–100.
  23. Brunt AM, Haviland J, Wheatley D, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet. 2020.
  24. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. The Lancet Oncology. 2019; 20(3): 352–360.
  25. COVID-19 Guidelines for Triage of Breast Cancer Patients. American College of Surgeons, ACS. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer.
  26. Dietz J, Moran M, Isakoff S, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181(3): 487–497.
  27. Clinical guide for the management of essential cancer surgery for adults during the coronavirus pandemic, 7 April 2020 Version 1, Publications approval reference: 001559. Academy of Medical Royal Colleges. . https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0239-Specialty-guide-Essential-Cancer-surgery-and-coronavirus-v1-70420.pdf.
  28. Cuzick J, Sestak I, Forbes J, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet. 2014; 383(9922): 1041–1048.
  29. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90(18): 1371–1388.
  30. Hwang E, Hyslop T, Hendrix L, et al. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). J Clin Oncol. 2020; 38(12): 1284–1292.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl